Vizsgálati helyszín
Salvador
Salvador, 40414-120, BrazíliaMég nincs intézményhez kötve
- 17futó vizsgálat
- 3lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 20 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis9 vizsgálat
- 1/2. fázis5 vizsgálat
- 2. fázis2 vizsgálat
- 2/3. fázis2 vizsgálat
- 1. fázis1 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz11 vizsgálat
- Toboroz6 vizsgálat
- Lezárult3 vizsgálat
- Fő szponzor
- GlaxoSmithKline18 vizsgálat
- ViiV Healthcare2 vizsgálat
Futó vizsgálatok
Toboroz
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916· 3. fázis· ViiV Healthcare· Forrás
Contact: Carlos Roberto Alves (principal investigator)
Toboroz
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101· 3. fázis· GlaxoSmithKline· Forrás
Contact: Edvan de Queiroz Crusoe (principal investigator)
Fut, nem toboroz
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
NCT06497504· 2. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
NCT06576271· 1. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT06472076· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249· 4. fázis· GlaxoSmithKline· Forrás
Toboroz
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· 3. fázis· GlaxoSmithKline· Forrás
Contact: Dyego Lucas Pereira Nunes (principal investigator)
Toboroz
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717· 2/3. fázis· GlaxoSmithKline· Forrás
Contact: Mittermayer Barreto Santiago (principal investigator)
Toboroz
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· 3. fázis· GlaxoSmithKline· Forrás
Contact: Livia Maria Andrade (principal investigator)
Toboroz
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
NCT05714839· 1/2. fázis· GlaxoSmithKline· Forrás
Contact: Edvan de Queiroz Crusoe (principal investigator)
Fut, nem toboroz
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
NCT07150104· 1/2. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
NCT07150091· 1/2. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
NCT07217184· 1/2. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
NCT04655976· 2/3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04126200· 1/2. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
NCT02362503· 3. fázis· ViiV Healthcare· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek